P. Malfertheiner-rekin lankidetzan egindako argitalpenak (15)

2024

  1. Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial

    United European Gastroenterology Journal

2023

  1. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial

    JHEP Reports, Vol. 5, Núm. 5

  2. Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression

    European Radiology, Vol. 33, Núm. 1, pp. 493-500

  3. Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309

2022

  1. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 13, pp. 4716-4726

  2. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

    Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 2, pp. 475-485

  3. Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial

    Frontiers in Gastroenterology, Vol. 1

  4. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

    Cancer Imaging, Vol. 22, Núm. 1

  5. Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Tria

    Clinical Cancer Research, Vol. 28, Núm. 17, pp. 3890-3901

  6. Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial

    Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 9, pp. 2487-2496

2021

  1. Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma

    Journal of Hepatology, Vol. 75, Núm. 6, pp. 1387-1396

  2. Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization

    EJNMMI Research, Vol. 11, Núm. 1

2020

  1. Reply to: “Toxicity and dosimetry in SORAMIC study”

    Journal of Hepatology

2019

  1. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma

    Journal of Hepatology, Vol. 71, Núm. 6, pp. 1164-1174

2015

  1. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: Analysis of the European multicentre trial SORAMIC

    Liver International, Vol. 35, Núm. 2, pp. 620-626